KR20220132567A - 신장 질환 치료에 사용하기 위한 항-αvβ8 인테그린 항체 - Google Patents

신장 질환 치료에 사용하기 위한 항-αvβ8 인테그린 항체 Download PDF

Info

Publication number
KR20220132567A
KR20220132567A KR1020227028722A KR20227028722A KR20220132567A KR 20220132567 A KR20220132567 A KR 20220132567A KR 1020227028722 A KR1020227028722 A KR 1020227028722A KR 20227028722 A KR20227028722 A KR 20227028722A KR 20220132567 A KR20220132567 A KR 20220132567A
Authority
KR
South Korea
Prior art keywords
antibody
αvβ8 integrin
antigen
amino acid
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227028722A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 제임스 베이커
스테파니 클레어 히스만
마리아 마르셀라 에레라
엘레나 리아르테 마린
캐롤 파트리샤 모레노-퀸
린 앤 머레이
핑 추이
얀리 우
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20220132567A publication Critical patent/KR20220132567A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227028722A 2020-01-27 2021-01-26 신장 질환 치료에 사용하기 위한 항-αvβ8 인테그린 항체 Pending KR20220132567A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966258P 2020-01-27 2020-01-27
US62/966,258 2020-01-27
PCT/EP2021/051753 WO2021151889A1 (en) 2020-01-27 2021-01-26 ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
KR20220132567A true KR20220132567A (ko) 2022-09-30

Family

ID=74561850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028722A Pending KR20220132567A (ko) 2020-01-27 2021-01-26 신장 질환 치료에 사용하기 위한 항-αvβ8 인테그린 항체

Country Status (18)

Country Link
US (1) US20230112035A1 (https=)
EP (1) EP4096785A1 (https=)
JP (1) JP7706458B2 (https=)
KR (1) KR20220132567A (https=)
CN (1) CN115151305A (https=)
AR (1) AR121193A1 (https=)
AU (1) AU2021213403B2 (https=)
BR (1) BR112022014633A2 (https=)
CA (1) CA3167390A1 (https=)
CL (1) CL2022001999A1 (https=)
CO (1) CO2022011661A2 (https=)
CR (1) CR20220392A (https=)
EC (1) ECSP22066085A (https=)
IL (1) IL294814A (https=)
MX (1) MX2022009165A (https=)
PH (1) PH12022551863A1 (https=)
TW (1) TWI854088B (https=)
WO (1) WO2021151889A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
US20260035468A1 (en) 2022-09-12 2026-02-05 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
TW202446789A (zh) * 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
SG2014014237A (en) * 2011-08-17 2014-07-30 Univ California Antibodies that bind integrin alpha-v beta-8
US20170073406A1 (en) * 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
PT3157561T (pt) 2014-06-17 2020-03-25 Univ California Anticorpos contra alfa-v beta-8 melhorados
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
CA3112523A1 (en) * 2018-08-08 2020-02-13 The General Hospital Corporation Integrin antagonists

Also Published As

Publication number Publication date
CR20220392A (es) 2022-09-07
JP7706458B2 (ja) 2025-07-11
CO2022011661A2 (es) 2022-08-30
CN115151305A (zh) 2022-10-04
TW202140554A (zh) 2021-11-01
JP2023511686A (ja) 2023-03-22
PH12022551863A1 (en) 2024-01-03
AU2021213403B2 (en) 2025-04-10
WO2021151889A1 (en) 2021-08-05
TWI854088B (zh) 2024-09-01
ECSP22066085A (es) 2022-09-30
CA3167390A1 (en) 2021-08-05
MX2022009165A (es) 2022-08-16
EP4096785A1 (en) 2022-12-07
AU2021213403A1 (en) 2022-09-15
BR112022014633A2 (pt) 2022-09-13
AR121193A1 (es) 2022-04-27
IL294814A (en) 2022-09-01
CL2022001999A1 (es) 2023-01-27
US20230112035A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
AU2018272311B2 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
EP2167542B1 (en) Neutralizing monoclonal antibody against human dll4
AU2021213403B2 (en) Anti-αvβ8 integrin antibodies for use in treating kidney disease
US10202454B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
AU2013306390B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP6564408B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
CN111741975B (zh) 抗血管生成素-2抗体及其用途
US10208125B2 (en) Anti-mucin 1 binding agents and uses thereof
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
JP2015525230A (ja) デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
EP3527225A1 (en) Composition containing anti-robo4 antibody and other agents
EP2841457B1 (en) Anti-robo4-antibody
TW201946658A (zh) 抗ｇｉｔｒ抗體及其用途
WO2023145844A1 (ja) 抗ヒトｃｘｃｌ１抗体
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК
WO2024260384A1 (en) Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof
RU2831785C2 (ru) Антитела к рмel17 и конъюгаты на их основе
HK40056594A (en) Bifunctional molecules with il-7 activity
HK1207093B (en) Anti-robo4-antibody

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902